Datar Genetics partners Apollo Hospitals for precision oncology

The partnership integrates molecular and genetic analysis with the diagnosis, treatment and monitoring of cancers and also explores precision matching for organ and bone marrow transplants.

Datar, in a statement, said it has developed technologies for non-invasive liquid biopsies, in vitro chemo-sensitivity assessment and ultra-high resolution gene expression-based therapy with low pain.

“Precision diagnosis gives patients the best chance to fight cancer upfront, save costs, reduce suffering and reduce time to productivity," said K. Hariprasad, president, Apollo Hospitals.